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Abstract
Background: Neuroethics describes several interdisciplinary topics exploring the application and implications of
engaging neuroscience in societal contexts. To explore this topic, we present Part 3 of a four-part bibliography of
neuroethics’ literature focusing on the “ethics of neuroscience.”
Methods: To complete a systematic survey of the neuroethics literature, 19 databases and 4 individual open-access
journals were employed. Searches were conducted using the indexing language of the U.S. National Library of
Medicine (NLM). A Python code was used to eliminate duplications in the final bibliography.
Results: This bibliography consists of 1137 papers, 56 books, and 134 book chapters published from 2002 through
2014, covering ethical issues in neuroimaging, neurogenetics, neurobiomarkers, neuro-psychopharmacology, brain
stimulation, neural stem cells, neural tissue transplants, pediatric-specific issues, dual-use, and general neuroscience
research issues. These works contain explanations of recent research regarding neurotechnology, while exploring
ethical issues in future discoveries and use.
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Introduction and background
As a discipline, neuroethics addresses and engages a
number of topics that are generated by the intersection
of brain science and applications in philosophy, medi-
cine, law, public life, and society (on the local and global
scales). In Part 2 of this bibliography [1], we provided a
list of works in the scholarly literature that address
the neuroscientific basis of moral decision-making and
actions, viz.- what Roskies somewhat colloquially refers
to as the “neuroscience of ethics” [2]. In Part 3, we
herein present a listing of works that discuss the “ethics
of neuroscience,” namely those issues, questions and
dilemmas generated by current and proposed neurosci-
entific research and its varied uses. The following bibli-
ographies provide systematic surveys from 2002 to 2014
of the neuroethics literature on translational neurosci-
ence, from “bench to bedside – and beyond” [3, 4] To be
sure, the topics are numerous, and list of works is long,
and include the following subjects:










b) transcranial brain stimulation/neuromodulation
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(i.e.: transcranial direct current stimulation,tDCS;
transcranial alternating current stimulation, tACS;
and transcranial magnetic stimulation, TMS)
c) deep brain stimulation (DBS)
d) brain-machine interfaces and neural prosthetics
Neural stem cells and tissue transplants
Issues concerning pediatric subjects/patients
Dual-use neuroscientific research
The topics covered involve defining the ethical issues
at hand, assessing patient outcomes, and deliberating on
quality of life considerations. These neuroethical deliber-
ations also focus on philosophical concepts such as per-
sonhood, authenticity, and identity [5, 6]. As an
analytical approach and discipline, neuroethics is both
pragmatic and pluralistic in its focus and scope [7]. The
pragmatism inherent in neuroethics acknowledges “…the
contingency of any/all neuroscientific knowledge, and an
advocacy for its use mutatis mutandis, irrespective of
whatever field” to which brain science is applied [8]. In
its pluralistic stance, neuroethics is increasingly oriented
toward, acknowledging and respectful of, and employing
multi-cultural perspectives, ideas, values, needs, contexts
and methods, as relevant to the realities of international
neuroscientific research and use upon the twenty first
century world stage [9–13].
As with Parts 1 and 2, we regard this as a “participa-
tory bibliography” to which readers are encouraged to
submit additional cites via the “Comments” section of
this paper, or by contacting the bibliographic manager at
bioethics@georgetown.edu. Through this process, the
bibliography can be and remain as current and accurate
as possible, so as to keep pace with ongoing develop-
ments in neuroscience, their translational use(s) in prac-
tice, and the ethical discourses and debates they foster.
Methods
Methods for systematically searching relevant literature
devoted to neuroethics are identical to those utilized in
Parts 1 and 2 of this bibliography [1, 14]. The United
States National Library of Medicine’s (NLM) indexing
language–MeSH (Medical Subject Headings)–was used
to generate the basic search strategy for each topic.
MeSH contains ethics-related terms developed for
BIOETHICSLINE, a specialty database devoted to bio-
ethical issues produced for NLM by the Kennedy Insti-
tute of Ethics from 1975 to 2000.
The following databases were utilized:
1) PubMed (https://pubmed.gov)
2) The NLM Catalog (http://www.ncbi.nlm.nih.gov/
nlmcatalog)
3) Academic Search Premier







11) Web of Knowledge/Web of Science (WoS)
12) Digital Public Library of America (DPLA)
(https://dp.la/)
13) Directory of Open Access Journals (DOAJ)
(https://doaj.org/)
14) Hathi Trust Digital Library (https://www.
hathitrust.org/)
15) European Library (http://www.theeuropeanlibrary.
org/tel4/)




19) Law and Neuroscience Bibliography (http://
www.lawneuro.org/bibliography.php)
Open access bioethics journals not contained in the
Directory of Open Access Journals (DOAJ) were indi-
vidually accessed and searched; these included:
1) Journal of Ethics and Social Philosophy from
the University of Southern California
(http://www.jesp.org/)
2) Journal of Mental Health Ethics from McMaster
University (http://www.jemh.ca/)
3) Journal of Practical Ethics (http://www.jpe.ox.ac.uk/)
from the Oxford Uehiro Centre for Practical Ethics
at the University of Oxford; and
4) Philosophers’ Imprint from the University of
Michigan (http://www.philosophersimprint.org/).
Results
The following bibliographies provide listings of 1137 ar-
ticles, 56 books, and 134 book chapters published from
2002 through 2014 that focus on the ethical issues in-
volved in translating neuroscientific research to clinical
practice.
Research general issues:
 Abi-Rached JM: The implications of the new
brain sciences. The 'Decade of the Brain' is over
but its effects are now becoming visible as
neuropolitics and neuroethics, and in the
emergence of neuroeconomies. EMBO Rep 2008,
9(12):1158-1162. doi: 10.1038/embor.2008.211.
 Alpert S: Total information awareness—forgotten
but not gone: lessons for neuroethics. Am J
Bioeth 2007, 7(5): 24-26.
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 Anderson JA, Eijkholt M, Illes J: Neuroethical
issues in clinical neuroscience research. Handb
Clin Neurol 2013, 118: 335-343. doi: 10.1016/B978-
0-444-53501-6.00028-7.
 Bergareche AM, da Rocha AC: Autonomy beyond
the brain: what neuroscience offers to a more
interactive, relational bioethics. AJOB Neurosci
2011, 2(3): 54-56. doi: 10.1080/21507740.2011.584948.
 Bird S: Potential for bias in the context of
neuroethics: commentary on “Neuroscience,
neuropolitics and neuroethics: the complex case
of crime, deception and FMRI”. Sci Eng Ethics
2012, 18(3): 593-600. doi: 10.1007/s11948-012-9399-y.
 Blakemore C et al.: Implementing the 3Rs in
neuroscience research: a reasoned approach.
Neuron 2012, 75(6):948-950. doi: 10.1016/j.neuron.
2012.09.001.
 Brosnan C, Cribb A, Wainwright SP, Williams C:
Neuroscientists’ everyday experiences of ethics:
the interplay of regulatory, professional,
personal and tangible ethical spheres. Sociol
Health Illn 2013, 35(8): 1133-1148. doi: 10.1111/
1467-9566.12026.
 Caulfield T, Ogbogu U: Biomedical research and
the commercialization agenda: a review of main
considerations for neuroscience. Account Res
2008, 15(4): 303-320. doi: 10.1080/
08989620802388788.
 Chatterjee A: The ethics of neuroenhancement.
Handb Clin Neurol 2013, 118: 323-34. doi: 10.1016/
B978-0-444-53501-6.00027-5.
 Cheshire WP: Neuroscience, nuance, and
neuroethics. Ethics Med 2006, 22(2): 71-3.
 Cheung EH: A new ethics of psychiatry:
neuroethics, neuroscience, and technology.
J Psychiatr Pract 2009, 15(5): 391-401. doi: 10.1097/
01.pra.0000361279.11210.14.
 Choudhury S, Nagel SK, Slaby J: Critical
neuroscience: linking neuroscience and society
through critical practice. Biosocieties 2009, 4:61-
77. doi:10.1017/S1745855209006437.
 Cohen PD et al.: Ethical issues in clinical
neuroscience research: a patient’s perspective.
Neurotherapeutics 2007, 4(3): 537-544. doi: 10.1016/
j.nurt.2007.04.008.
 Crozier S: [Neuroethics: ethical issues in
neurosciences]. Rev Prat 2013, 63(5): 666-669.
 Decker M, Fleischer T: Contacting the
brain—aspects of a technology assessment of
neural implants. Biotechnol J 2008, 3(12): 1502-
1510. doi: 10.1002/biot.200800225.
 Di Luca M et al.: Consensus document on
European brain research. Eur J Neurosci 2011,
33(5):768-818. doi: 10.1111/j.1460-9568.2010.07596.x.
 Eaton ML, Illes J: Commercializing cognitive
neurotechnology–the ethical terrain. Nat
Biotechnol 2007, 25(4): 393-397. doi:10.1038/
nbt0407-393.
 Farah MJ: Neuroethics: the practical and the
philosophical. Trends Cogn Sci 2005, 9(1): 34-40.
doi: 10.1016/j.tics.2004.12.00.
 Farah MJ: Social, legal, and ethical implications
of cognitive neuroscience: “neuroethics” for
short. J Cogn Neurosci 2007, 19(3): 363-4. doi:
10.1162/jocn.2007.19.3.363.
 Fellows LK, Stark M, Berg A, Chatterjee A:
Patient registries in cognitive neuroscience
research: advantages, challenges, and practical
advice. J Cogn Neurosci 2008, 20(6): 1107-1113.
doi: 10.1162/jocn.2008.20065.
 Fins JJ: From psychosurgery to neuromodulation
and palliation: history’s lessons for the ethical
conduct and regulation of neuropsychiatric
research.Neurosurg Clin N Am 2003, 14(2): 303-19.
doi: 10.1016/S1042-3680(02)00118-3.
 Fischer MMJ: The BAC [bioethics advisory
committee] consultation on neuroscience and
ethics: an anthropologist’s perspective. Innovation
2013, 11(2): 3-5.
 Ford PJ: Special section on clinical neuroethics
consultation: introduction. HEC Forum 2008,
20(3): 311-4. doi: 10.1007/s10730-008-9081-6.
 Fry CL: A descriptive social neuroethics is
needed to reveal lived identities. Am J Bioeth
2009, 9(9): 16-7. doi: 10.1080/15265160903098580
 Fuchs T: Ethical issues in neuroscience. Curr Opin
Psychiatry 2006, 19(6): 600-607. doi: 10.1097/01.yco.
0000245752.75879.26.
 Fukushi T, Sakura O, Koizumi H: Ethical
considerations of neuroscience research: the
perspectives on neuroethics in Japan. Neurosci Res
2007, 57(1): 10-16. doi: 10.1016/j.neures.2006.09.004.
 Fukushi T, Sakura O: Exploring the origin of
neuroethics: from the viewpoints of expression
and concepts. Am J Bioeth 2008, 8(1): 56-57. doi:
10.1080/15265160701839672.
 Fukushi T, Sakura O: [Introduction of
neuroethics: out of clinic, beyond academia in
human brain research]. Rinsho Shinkeigaku 2008,
48(11): 952-954. doi: 10.5692/clinicalneurol.48.952.
 Galpern WR et al.: Sham neurosurgical
procedures in clinical trials for neuro
degenerative diseases: scientific and
ethical considerations. Lancet Neurol 2012,
11(7): 643-650. doi: 10.1016/S1474-4422
(12)70064-9.
 Glannon W: Neuroethics. Bioethics 2006, 20(1): 37-
52. doi: 10.1111/j.1467-8519.2006.00474.x.
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 Gray JR, Thompson PM: Neurobiology of
intelligence: science and ethics. Nat Rev Neurosci
2004, 5(6): 471-482. doi: 10.1038/nrn1405.
 Gutiérrez G: Neurobiología y contenido material
universal de la ética: reflexiones a partir del
modelo neurobiológico de Antonio Damasio.
Utop Prax Latinoam 2006, 11(33): 9-38.
 Hauser SL: What ethics integration looks like in
neuroscience research. Ann Neurol 2014, 75(5):
623-624. doi: 10.1002/ana.24177.
 Henry S, Plemmons D: Neuroscience,
neuropolitics and neuroethics: the complex
case of crime, deception and FMRI. Sci Eng
Ethics 2012, 18(3): 573-591. doi: 10.1007/s11948-
012-9393-4.
 Illes J: Empirical neuroethics: can brain imaging
visualize human thought? why is neuroethics
interested in such a possibility? EMBO Rep 2007,
8: S57-S60. doi: 10.1038/sj.embor.7401007.
 Illes J: Empowering brain science with
neuroethics. Lancet 2010, 376(9749): 1294-1295.
doi: 10.1016/S0140-6736(10)61904-6.
 Illes J et al.: International perspectives on
engaging the public in neuroethics. Nat Rev
Neurosci 2005, 6(12): 977-982. doi:10.1038/nrn1808.
 Illes J, Raffin TA: Neuroethics: an emerging new
discipline in the study of brain and cognition.
Brain Cogn 2002, 50(3): 341-344. doi: 10.1016/
s0278-2626(02)00522-5.
 Illes J, Bird SJ: Neuroethics: a modern context for
ethics in neuroscience. Trends Neurosci 2006,
29(9): 511-517. doi: 10.1016/j.tins.2006.07.002.
 Illes J et al.: Neurotalk: improving the
communication of neuroscience research.
Nat Rev Neurosci 2010, 11(1): 61-69. doi: 10.1038/
nrn2773.
 Illes J et al.: Reducing barriers to ethics in
neuroscience. Front Hum Neurosci 2010, 4: 167.
doi: 10.3389/fnhum.2010.00167.
 Jonsen AR: What it means to “map” the field of
neuroethics. Cerebrum 2002, 4(3): 71-72.
 Jox RJ, Schöne-Seifert B, Brukamp K: [Current
controversies in neuroethics]. Nervenarzt 2013,
84(10):1163-1164. doi: 10.1007/s00115-013-3731-x.
 Justo L, Erazun F: Neuroethics needs an
international human rights deliberative frame.
AJOB Neurosci 2010, 1(4): 17-18. doi: 10.1080/
21507740.2010.515559.
 Kirschenbaum SR: Patenting basic research:
myths and realities. Nat Neurosci 2002, 5: Suppl
1025-1027. doi: 10.1038/nn932.
 Klein E: Is there a need for clinical
neuroskepticism? Neuroethics 2011, 4(3): 251-259.
doi: 10.1007/s12152-010-9089-x
 Kretzschmar H: Brain banking: opportunities,
challenges and meaning for the future. Nat Rev
Neurosci 2009, 10(1): 70-78. doi: 10.1038/nrn2535.
 Labuzetta JN, Burnstein R, Pickard J: Ethical issues
in consenting vulnerable patients for neuroscience
research. J Psychopharmacol 2011, 25(2): 205-210.
doi: 10.1177/0269881109349838.
 Lanzilao E, Shook JR, Benedikter R, Giordano J:
Advancing neuroscience on the 21st-century
world stage: the need for and a proposed
structure of an internationally relevant
neuroethics. Ethics Biol Eng Med 2013, 4(3), 211-
229. doi: 10.1615/EthicsBiologyEngMed.2014010710.
 Leonardi M et al.: Pain, suffering and some
ethical issues in neuroscience research.
J Headache Pain 2004, 5(2): 162-164. doi: 10.1007/
s10194-004-0088-3.
 Leshner AI: Ethical issues in taking neuroscience
research from bench to bedside. Cerebrum 2004,
6(4): 66-72.
 Lieberman MD: Social cognitive neuroscience: a
review of core processes. Annu Rev Psychol 2007, 58:
259-289. doi: 10.1146/annurev.psych.58.110405.085654.
 Lombera S, Illes J: The international dimensions
of neuroethics. Dev World Bioeth 2009, 9(2):57-64.
doi: 10.1111/j.1471-8847.2008.00235.x.
 Mandel RJ, Burger C: Clinical trials in neurological
disorders using AAV vectors: promises and
challenges. Curr Opin Mol Ther 2004, 6(5):482-490.
 Mauron A: [Neuroethics]. Rev Med Suisse 2006,
2(74): 1816.
 Miller FG, Kaptchuk TJ: Deception of subjects in
neuroscience: an ethical analysis. J Neurosci 2008,
28(19): 4841-4843. doi: 10.1523/JNEUROSCI.1493-
08.2008.
 Morein-Zamir S, Sahakian BJ: Neuroethics and
public engagement training needed for
neuroscientists. Trends Cogn Sci 2010, 14(2): 49-51.
doi: 10.1016/j.tics.2009.10.007.
 Northoff G: [Methodological deficits in neuroethics:
do we need theoretical neuroethics?]. Nervenarzt
2013, 84(10):1196-1202. doi: 10.1007/s00115-013-3732-9.
 Nutt DJ, King LA, Nichols DE: Effects of Schedule
1 drug laws on neuroscience research and
treatment innovation. Nat Rev Neurosci 2013,
14(8): 577-585. doi: 10.1038/nrn3530.
 Olesen J: Consensus document on European
brain research. J Neurol Neurosurg Psychiatry 2006,
77 (Supp 1):i1-i49.
 Parens E, Johnston J: Does is make any sense to
speak of neuroethics: three problems with
keying ethics to hot new science and technology.
EMBO Rep 2007, 8: S61-S64. doi:10.1038/
sj.embor.7400992.
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 Parker LS, Kienholz ML: Disclosure issues in
neuroscience research. Account Res 2008, 15(4):
226-241. doi: 10.1080/08989620802388697.
 Paylor B, Longstaff H, Rossi F, Illes J: Collision or
convergence: beliefs and politics in neuroscience
discovery, ethics, and intervention. Trends Neurosci
2014, 37(8): 409-412. doi: 10.1016/j.tins.2014.06.001.
 Perrachione TK, Perrachione JR: Brains and brands:
developing mutually informative research in
neuroscience and marketing. J Consumer Behav
2008, 7: 303-318. doi: 10.1002/cb.253.
 Pfaff DW, Kavaliers M, Choleris E: Response to Peer
Commentaries on Mechanisms Underlying an
Ability to Behave Ethically—Neuroscience
Addresses Ethical Behaviors: Transitioning From
Philosophical Dialogues to Testable Scientific
Theories of Brain and Behavior. Am J Bioeth 2008,
8(5): W1-W3. doi: 10.1080/15265160802180117.
 Pickersgill M: Ordering disorder: knowledge
production and uncertainty in neuroscience
research. Sci Cult (Lond) 2011, 20(1): 71-87. doi:
10.1080/09505431.2010.508086.
 Pierce R:What a tangled web we weave: ethical
and legal implications of deception in recruitment.
Account Res 2008, 15(4): 262-282. doi: 10.1080/
08989620802388713.
 Racine E, Waldman S, Rosenberg J, Illes J:
Contemporary neuroscience in the media.
Soc Sci Med 2010, 71(4): 725-733. doi: 10.1016/
j.socscimed.2010.05.017.
 Racine E: Identifying challenges and conditions for
the use of neuroscience in bioethics. Am J Bioeth
2007, 7(1): 74-76. doi: 10.1080/15265160601064363.
 Racine E, Illes J: Responsabilités neuroéthiques/
neuroethical responsibilities. Can J Neurol Sci
2006, 33(3): 260-268, 269-277. doi: 10.1017/
S0317167100005126.
 Ramos-Zúñiga R: [Neuroethics as a new
epistemological perspective in neuroscience].
Rev Neurol 2014, 58(4): 145-146.
 Robillard JM et al.: Untapped ethical resources for
neurodegeneration research. BMC Med Ethics
2011, 12: 9. doi: 10.1186/1472-6939-12-9.
 Rose N: The human brain project: social and
ethical challenges.Neuron 2014, 82(6):1212-1215.
doi:10.1016/j.neuron.2014.06.001.
 Rose N: The human sciences in a biological age.
Theory Cult Soc 2013, 30(1): 3-34. doi: 10.1177/
0263276412456569.
 Roskies A: Neuroethics for the new millenium.
Neuron 2002, 35(1): 21-23. doi: 10.1016/S0896-
6273(02)00763-8.
 Schreiber D: On social attribution: implications
of recent cognitive neuroscience research for
race, law, and politics. Sci Eng Ethics 2012, 18(3):
557-566. doi: 10.1007/s11948-012-9381-8.
 Shook JR, Giordano J: A principled and
cosmopolitan neuroethics: considerations for
international relevance. Philos Ethics Humanit
Med 2014, 9:1. doi: 10.1186/1747-5341-9-1.
 Stevenson S et al.: Neuroethics, confidentiality,
and a cultural imperative in early onset
Alzheimer’s disease: a case study with a First
Nation population. Philos Ethics Humanit Med
2013, 8: 15. doi: 10.1186/1747-5341-8-15.
 Synofzik M: Interventionen zwischen gehirn und
geist: eine ethische analyse der neuen
moglichkeiten der neurowissenschaften
[Intervening between brain and mind: an ethical
analysis of the new possibilities of the
neurosciences]. Fortschr Neurol Psychiatr 2005,
73(10):596-604. doi:10.1055/s-2004-830292.
 Swift TL: Sham surgery trial controls: perspectives
of patients and their relatives. J Empir Res Hum Res
Ethics 2012, 7(3): 15-28. doi: 10.1525/jer.2012.7.3.15.
 Weisberg DS et al.: The seductive allure of
neuroscience explanations. J Cogn Neurosci 2008,
20(3): 470-477. doi: 10.1162/jocn.2008.20040.
 Winslade W: Severe brain injury: recognizing the
limits of treatment and exploring the frontiers
of research. Camb Q Healthc Ethics 2007, 16(2):
161-168. doi: 10.1017/S0963180107070181.
 Wolpe PR: Ethics and social policy in research on
the neuroscience of human sexuality. Nature
Neuroscience 2004, 7(10): 1031-1033. 10.1038/nn1324.
 Zimmerman E, Racine E: Ethical issues in the
translation of social neuroscience: a policy
analysis of current guidelines for public dialogue
in human research. Account Res 2012, 19(1): 27-46.
doi: 10.1080/08989621.2012.650949.
Books:
 Ackerman S: Hard Science, Hard Choices: Facts,
Ethics, and Policies Guiding Brain Science Today.
New York: Dana Press; 2006.
 Centre for Educational Research and Innovation,
Organisation for Economic Co-operation and
Development. Understanding the Brain: The Birth of
a Learning Science. Paris: OECD; 2007.
 Harrington M: The Design of Experiments in
Neuroscience. Thousand Oaks, CA: Sage; 2011.
 National Research Council (U.S.). Committee on
Military and Intelligence Methodology for Emergent
Neurophysiological and Cognitive/Neural Science
Research in the Next Two Decades. Emerging
Cognitive Neuroscience and Related Technologies.
Washington, DC: National Academies Press; 2008.
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 Sousa DA: Brainwork: The Neuroscience Behind How
We Lead Others. Bloomington, IN: Triple Nickel
Press; 2012.
 Taylor KE: The Brain Supremacy: Notes from the
Frontiers of Neuroscience. Oxford: Oxford University
Press; 2012.
Book chapters:
 Alves WM: Ethical considerations in
neuroemergency clinical trials. In Handbook of
Neuroemergency Clinical Trials. Edited by Wayne
M. Alves. Amsterdam: Elsevier Academic Press;
2006: 257-273.
 Anderson JA, Eijkholt M, Illes J: Neuroethical
issues in clinical neuroscience research. In
Ethical and Legal Issues in Neurology. Edited by
James L. Bernat, H. Richard Beresford. Edinburgh:
Elsevier; 2013: 335-344.
 Birge S: Brainhood, selfhood, or “meat with a
point of view”: the value of fiction for
neuroscientific research and neurological
medicine. In Neuroscientific Turn:
Transdisciplinarity in the Age of the Brain. Edited by
Melissa M. Littlefield, Jenell M. Johnson. Ann Arbor,
MI: University of Michigan Press; 2012: 89-104.
 Borck C: Toys are us: models and metaphors in
brain research. In Critical Neuroscience: A Handbook
of the Social and Cultural Contexts of Neuroscience.
Edited by Suparna Choudhury, Jan Slaby. Chichester,
West Sussex: Wiley-Blackwell; 2012: 113-134.
 Detre J, Bockow TB: Incidental findings in
magnetic resonance imaging research. In
Neuroethics in Practice. Edited by Anjan Chatterjee,
Martha J. Farah. New York: Oxford University Press;
2012: 120-127.
 Ford PJ, Deshpande A: The ethics of surgically
invasive neuroscience research. In Ethical and Legal
Issues in Neurology. Edited by James L. Bernat, H.
Richard Beresford. Edinburgh: Elsevier; 2013: 315-322.
 Giordano J: Integrative convergence in
neuroscience: trajectories, problems and the
need for a progressive neurobioethics. In
Technological Innovations in Sensing and Detection
of Chemical, Biological, Radiological, Nuclear
Threats and Ecological Terrorism. Edited by A.
Vaseashta, Eric Braman, Philip Susmann. Dordrecht:
Springer; 2012: 115-130.
 Giordano J, Waters P: What might renewed focus
on brain research mean for the prevention and
care of brain injury and its effects? In their Brain
Injury: Spectrum Effects and Implications. Edited by
James Giordano and Patrick Waters. Arlington, VA:
Potomac Institute Press; 2013: xiii-xxiv.
 Hochberg L, Cochrane T: Implanted neural
interfaces: ethics in treatment and research.
In Neuroethics in Practice. Edited by Anjan
Chatterjee, Martha J. Farah. New York: Oxford
University Press; 2012: 234-250.
 Hurst S: Clinical research on conditions affecting
cognitive capacity. In The Oxford Handbook of
Neuroethics. Edited by Judy Illes and Barbara J.
Sahakian. Oxford: Oxford University Press; 2011:
513-528.
 Kim SYH: Competence for informed consent for
treatment and research. In Neuroethics in Practice.
Edited by Anjan Chatterjee, Martha J. Farah. New
York: Oxford University Press; 2012: 83-95.
 Linden D: The ethics and politics of brain
control. In his Brain Control: Developments in
Therapy and Implications for Society. London:
Palgrave Macmillan; 2014: 131-171.
 Miller FG, Fins JJ: Protecting human subjects in
brain research: a pragmatic perspective. In
Neuroethics: Defining the Issues in Theory, Practice,
and Policy. Edited by Judy Illes. Oxford: Oxford
University Press; 2006: 123-140.
 Murray S, Yanagi MA: Transitioning brain research:
from bench to battlefield. In Neurotechnology in
National Security and Defense: Practical Considerations,
Neuroethical Concerns. Edited by James Giordano. Boca
Raton: CRC Press; 2014 [2015]:11-22.
 Racine E: Public understanding of neuroscience
innovation and emerging interpretations of
neuroscience research. In his Pragmatic
Neuroethics: Improving Treatment and
Understanding of the Mind-Brain. Cambridge,
Mass.: MIT Press; 2010: 97-120.
 Wolf SM: Incidental findings in neuroscience
research: a fundamental challenge to the
structure of bioethics and health law. In The
Oxford Handbook of Neuroethics. Edited by Judy
Illes and Barbara J. Sahakian. Oxford: Oxford
University Press; 2011: 623-634.
Neuroimaging:
 Aggarwal NK: Neuroimaging, culture, and
forensic psychiatry. J Am Acad Psychiatry Law
2009, 37(2): 239-244.
 Aktunç E.: Tackling Duhemian problems: an
alternative to skepticism of neuroimaging in
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Discussion and conclusions
As demonstrated by this bibliography, the breadth and
depth of the literature addressing the “ethics of neurosci-
ence” is extensive. Indeed, many of the ethical issues fos-
tered by brain science affect the foci, scope and conduct
of clinical care, as much of neuroscientific and neuro-
technological research is oriented and being explicitly di-
rected toward translational applications in medicine. In
the clinical milieu, the use of various neuroscientific ap-
proaches and tools evokes additional, and frequently
more provocative, if not contentious issues, questions,
problems and debates, and calls forth possible solutions
that are specific to patient care, and the execution and
sustainability of both (neuro)science and medicine as vi-
able and valuable public good(s). Literature addressing
such applications of brain science will be presented in
Part 4 of this bibliographic series.
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